Senechal, MarioCouture, ChristianMorin, JoëlleLeblanc, Marie-HeleneBourgault, ChristineCantin, BernardDemers, Sabrina2026-04-132012-10Experimental and Clinical Transplantation, Cilt, 10, Sayı, 5, 2012 ss. 513-5181304-0855https://hdl.handle.net/11727/14920Posttransplant lymphoproliferative disorders remain an uncommon complication of heart transplant with a high mortality rate reported after conventional therapies. Four patients with posttransplant lymphoproliferative disorders, of whom 3 were CD20 positive, received intravenous dosages of rituximab, 375 mg/m2, weekly, for 6 ± 2 weeks. The overall response rate was 75% with 3 complete responses (CD20 positive) and 1 case of progressive disease (CD20 negative). Rituximab should be considered as a first-line therapy for patients with CD20 positive posttransplant lymphoproliferative disorders.enRituximabLymphomaHeart transplantCD20Case Report1052146-8427